Robert Nelsen
Sits on 5 boards. Overboarded · 5 public boards Last updated September 27, 2026
Time on boards
- Boards served
- 5
- Current seats
- 5
- Board service
- 14 years
- Director since
- 2023
14 years of board service in total across 5 boards, counting each seat separately. Longest: Sana Biotechnology Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Sana Biotechnology Inc. June 4, 202691.9%
-
Sana Biotechnology Inc. June 8, 202386.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 22, 2026 | Kardigan Inc. | Open-market purchase | +1,250,000 | $16.00 | $20,000,000 |
| Aug 1, 2025 | Prime Medicine Inc. | Open-market purchase | +3,030,300 | $3.30 | $9,999,990 |
| Jun 10, 2024 | Rapport Therapeutics Inc. | Derivative conversion | +3,728,738 | — | — |
| May 30, 2024 | Vir Biotechnology Inc. | Grant or award | +8,000 | — | — |
| Feb 15, 2024 | Prime Medicine Inc. | Open-market purchase | +3,200,000 | $6.25 | $20,000,000 |
| Feb 8, 2024 | Sana Biotechnology Inc. | Open-market purchase | +363,637 | $5.50 | $2,000,004 |
| Feb 8, 2024 | Sana Biotechnology Inc. | Open-market purchase | +727,272 | $5.50 | $3,999,996 |
| Feb 8, 2024 | Sana Biotechnology Inc. | Open-market purchase | +727,272 | $5.50 | $3,999,996 |
| Sep 29, 2023 | Neumora Therapeutics Inc. | Open-market purchase | +34,560 | $13.98 | $483,149 |
| Sep 28, 2023 | Neumora Therapeutics Inc. | Open-market purchase | +16,841 | $13.06 | $219,943 |
| Sep 28, 2023 | Neumora Therapeutics Inc. | Open-market purchase | +25,110 | $13.69 | $343,756 |
| Sep 27, 2023 | Neumora Therapeutics Inc. | Open-market purchase | +24,504 | $12.31 | $301,644 |
| Sep 26, 2023 | Neumora Therapeutics Inc. | Open-market purchase | +34,000 | $11.73 | $398,820 |
| Sep 25, 2023 | Neumora Therapeutics Inc. | Open-market purchase | +30,773 | $10.80 | $332,348 |
| Sep 25, 2023 | Neumora Therapeutics Inc. | Open-market purchase | +29,967 | $11.65 | $349,116 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.